Amdoxovir

Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma.^[1]

Amdoxovir

Clinical data
ATC code	none
Identifiers
IUPAC name [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
CAS Number	145514-04-1 Y
PubChem CID	124088
ChemSpider	110576 Y
UNII	54I81H0M9C
KEGG	D02890 Y
ChEMBL	ChEMBL458876 Y
NIAID ChemDB	005431
CompTox Dashboard (EPA)	DTXSID801027435
Chemical and physical data
Formula	C9H12N6O3
Molar mass	252.234 g·mol−1
3D model (JSmol)	Interactive image
SMILES n2c1c(nc(nc1n(c2)[C@@H]3O[C@@H](OC3)CO)N)N
InChI InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1 Y Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N Y
(verify)

Amdoxovir was in advanced Phase II clinical trials around 2010.^[2] In 2013, a Phase II trial was terminated^[3] and another was withdrawn before it started.^[4] No further studies appear to have been done.